Jerby-Arnon L, Pfetzer N, Waldman YY, et al. Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. Cell. 2014;158(5):1199-209. doi:10.1016/j.cell.2014.07.027.

Cajanus K, Holmström EJ, Wessman M, Anttila V, Kaunisto MA, Kalso E. Effect of endocannabinoid degradation on pain: role of FAAH polymorphisms in experimental and postoperative pain in women treated for breast cancer. Pain. 2016;157(2):361-9. doi:10.1097/j.pain.0000000000000398.

Vasudevan KM, Barbie DA, Davies MA, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009;16(1):21-32. doi:10.1016/j.ccr.2009.04.012.

Germain AR, Carmody LC, Nag PP, et al. Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells. Bioorg Med Chem Lett. 2013;23(6):1834-8. doi:10.1016/j.bmcl.2013.01.025.

Del Vecchio CA, Feng Y, Sokol ES, et al. De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling. PLoS Biol. 2014;12(9):e1001945. doi:10.1371/journal.pbio.1001945.

Tabb DL, Wang X, Carr SA, et al. Reproducibility of Differential Proteomic Technologies in CPTAC Fractionated Xenografts. J Proteome Res. 2016;15(3):691-706. doi:10.1021/acs.jproteome.5b00859.

Hoshida Y, Brunet J-P, Tamayo P, Golub TR, Mesirov JP. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One. 2007;2(11):e1195. doi:10.1371/journal.pone.0001195.

Hagerstrand D, Tong A, Schumacher SE, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 2013;3(9):1044-57. doi:10.1158/2159-8290.CD-12-0592.

Perry JRB, Day F, Elks CE, et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature. 2014;514(7520):92-7. doi:10.1038/nature13545.

Krier J, Barfield R, Green RC, Kraft P. Reclassification of genetic-based risk predictions as GWAS data accumulate. Genome Med. 2016;8(1):20. doi:10.1186/s13073-016-0272-5.